Treatment using allogeneic γ9δ2 T cells for recurrent blood cancers

Is this trial a fit for you?

A plain-English reading of the study's rules. Only the study team can confirm whether you qualify.

What this trial studies

This open-label clinical study aims to evaluate the safety and tolerance of allogeneic γ9δ2 T cell injections in patients with recurrent hematologic tumors following allogeneic hematopoietic stem cell transplantation. The study will assess the in vivo dynamics of these T cells and explore the appropriate therapeutic dose. Participants will receive a combination of allogeneic γ9δ2 T cells along with Fludarabine, Cyclophosphamide, and Zoredronic acid as part of their treatment regimen.

Why it matters

Who can join: the full rules

Inclusion Criteria:

1. Age 12-65 (inclusive)；
2. Patients with recurrent hematologic tumors after allogeneic hematopoietic stem cell transplantation；
3. Basically normal liver and kidney function (as demonstrated by the following laboratory tests prior to initial γ9δ2 T cell therapy)

   * Alanine transaminase/aspartate transaminase \< 2.5×ULN；
   * serum creatinine \< 1.5×ULN；
   * total bilirubin level \< 1.5×ULN；
4. No obvious hereditary disease;
5. Normal cardiac function, cardiac ejection index above 55%;
6. Women of reproductive age (15 to 49 years) must undergo a pregnancy test within 7 days before starting treatment and the result is negative, and use contraception during the clinical trial period and within 3 months after the last cell transfusion;
7. Sign informed consent.

Exclusion Criteria:

1. Patients with simple extramedullary recurrence;
2. Pregnant and lactating women;
3. Organ failure;

   * Heart: Ⅲ level and Ⅳ level;
   * Liver: reach the grade C Child - Turcotte liver function;
   * Kidney, renal failure and uremia period;
   * Lung: symptoms of severe respiratory failure;
   * Brain: consciousness disorder.
4. Patients with a history of solid organ transplantation;
5. Uncontrollable infectious diseases or other serious diseases, including but not limited to infections (such as HIV positive), congestive heart failure, unstable angina, arrhythmia, psychosis, or restricted social circumstances or those that the attending physician considers to pose unpredictable risks;
6. Patients with systemic autoimmune diseases or primary immunodeficiency;
7. Patients with allergic constitution;
8. Use of systemic steroid drugs;
9. Chronic diseases requiring the use of immunological agents or hormone herapy;
10. Prior treatment with any other immune cells;
11. Participated in similar clinical trials within 30 days;
12. Received radiation therapy within 4 weeks from the time of enrollment;
13. Researchers don't think clinical trials are appropriate for other reasons.

Where it's running

• Anhui Provincial Hospital
  Hefei, Anhui, China Recruiting

Study contacts

• Principal investigator: Zhu Xiaoyu, Ph.D — Director of Hematology Department, Anhui Provincial Hospital
• Study coordinator: Zhu Xiaoyu, Ph.D
• Email: xiaoyuz@ustc.edu.cn
• Phone: +86 15255456091

Similar studies

Other studies for the same condition or treatment. Recruiting studies are listed first.

• Romiplostim to help platelets grow after donor stem cell transplant

  This phase II trial tests whether weekly romiplostim helps patients over 18 who receive a haploidentical or fully matched unrelated donor stem cell transplant to engraft platelets faster than best supportive care.

  Recruiting Phase 2 Chinese PLA General Hospital · Beijing, Beijing Municipality · NCT07919977

• IL-5 CAR-T therapy for refractory or relapsed eosinophilic leukemia

  We will test whether IL-5 CAR-T cells can help adults with CD125-positive refractory or relapsed eosinophilic leukemia.

  Recruiting Phase 1 Zhejiang University · Hangzhou, Zhejiang · NCT07257640

• Exploring immune defects in young patients with blood disorders

  This study is trying to find out how immune system problems affect young people under 25 with blood disorders like autoimmune issues and bone marrow failure.

  Recruiting at 7 sites Meyer Children's Hospital IRCCS · Montreal, Canada and 6 other locations · NCT06857604

• HLA mismatched stem cell transplantation for hematologic diseases

  This study is testing if using stem cells from donors who aren't a perfect match can help people with blood cancers get the treatment they need when they can't find a suitable donor.

  Recruiting Phase 1 Zhejiang University · Hangzhou, China · NCT06809699

• Go Wish Game to support advance care planning for adults with cancer or blood cancers

  This project tries the Go Wish Game to help adults with refractory leukemia, lymphoma, multiple myeloma, or advanced solid tumors and their caregivers have end-of-life conversations and complete advance care planning.

  Recruiting Azienda USL Reggio Emilia - IRCCS · Reggio Emilia · NCT06795815

• Home blood transfusions for people with advanced blood cancers in hospice

  The study will test whether offering home blood transfusions to adults with advanced or relapsed blood cancers who are eligible for hospice helps improve quality of life, mood, and end-of-life care.

  Recruiting at 2 sites Dana-Farber Cancer Institute · Boston, Massachusetts and 1 other locations · NCT06487247

How to take part

1. Review the eligibility criteria above with your treating physician.
2. Check the official listing on ClinicalTrials.gov for the latest contact details and recruitment status.
3. Contact the study coordinator or principal investigator to ask for pre-screening. Pre-screening is free and never obligates you to enroll.